Genflow Biosciences Stock Price, News & Analysis

Genflow Biosciences (OTC:GENFF) disclosure shows Jonathan Mark Swann increased his holding to 11.32% of voting rights in Genflow Biosciences on 23-Oct-2025, up from 8.40% in the prior notification.

The resulting position equals 55,861,278 voting rights. No financial instruments were reported; the notification lists completion in London on 23-Oct-2025 and states no additional information.

Genflow Biosciences (LSE:GENF / OTCQB:GENFF) announced publication of its second European patent application (Application No. 23821586.7; Publication No. EP4630038) titled “SIRT6 Variant for NASH” in the European Patent Bulletin on October 22, 2025.

The publication follows entry into the European phase under the PCT and provides provisional protection under Article 67(3) EPC, enabling retroactive damages for infringing acts after publication once the patent is granted and national validations are completed. The filing complements the company’s earlier EP4338267 SIRT6 variant application and is presented as part of Genflow’s strategy to expand IP coverage across metabolic and age‑related disorders and support upcoming clinical programs.

Genflow Biosciences (LSE:GENF / OTCQB:GENFF) announced that the European Patent Office published its Euro‑PCT application in the EPO Bulletin on 15 October 2025, recognizing the patentability of claims for a SIRT6 variant patent (EP publication No. EP4338267; application No. 22808414.1; European publication EP4630038).

The publication places the application in the final pre‑grant phase under Article 67(3) EPC and activates provisional protection across participating EPO member states pending national validations. Genflow must bring the description into compliance with the claims in response to an Official Letter before the EPO will issue the intention to grant.

Genflow Biosciences (OTCQB:GENFF) provided an update on its Dog Aging (GF-1004) proof-of-concept trial testing a centenarian SIRT6 gene therapy in elderly dogs.

Repeat administration was completed in October 2025 in the randomized, controlled study of 28 beagles aged 10+, with no ill or adverse effects observed after the second dosing. The dogs enter a follow-up period expected to conclude in January 2026. The company highlighted potential animal-health commercial opportunities and continued partnership development while advancing to next-stage evaluation.

Genflow Biosciences (LSE:GENF / OTCQB:GENFF) announced on 9 October 2025 that it has terminated the previously announced subscription from 2 October 2025 and completed an Alternative Transaction raising gross proceeds of £440,000 via an allotment of 40,000,000 new ordinary shares at 1.1 pence per share. The shares were allotted to CEO Eric Leire, who will direct 35,454,546 shares to a consortium of existing shareholders and retain 4,545,454 shares.

Concurrent warrants will be issued one-for-one, exercisable at 1.2 pence for 24 months. Admission of the new shares is expected on or around 16 October 2025, after which total issued share capital and voting rights will be 493,547,942. The allotment used an employee-offer prospectus exemption under the UK Prospectus Regulation.

Genflow Biosciences (OTCQB:GENFF) has announced a significant equity issuance, raising £340,000 (before expenses) through the allotment of 40,000,000 new ordinary shares at 0.85 pence per share, representing a 35% discount to the October 1, 2025 bid price.

The transaction involves CEO Eric Leire subscribing to the shares under the employee offer exemption, who will then direct their issue to an institution for immediate sale to an identified purchaser. The purchaser will receive one-for-one warrants exercisable for 24 months at 1.2 pence. Upon admission, expected around October 9, 2025, the company's total issued shares will increase to 493,547,942.

Genflow Biosciences (OTCQB:GENFF) has successfully raised £340,000 through the issuance of 40,000,000 new ordinary shares at 0.85 pence per share. The transaction involves CEO Eric Leire initially subscribing to the shares under an employee offer exemption, who will then direct their issuance to an institution for immediate sale to an identified purchaser.

The purchaser will receive one-for-one warrants exercisable for 24 months at 1.2 pence. Upon admission of the new shares expected around October 9, 2025, the company's total issued shares will increase to 493,547,942. The funding will provide essential working capital and support ongoing dog studies while awaiting the Wallonia region grant's first payment.

Genflow Biosciences (OTCQB:GENFF) has reported its H1 2025 results, highlighting significant progress in both human and animal health programs focused on SIRT6 centenarian-based gene therapies. The company has strategically repositioned its GF-1002 therapy to target advanced MASH with fibrosis, addressing an underserved market segment.

Key financial metrics show cash reserves of £279,445 as of June 30, 2025, with administration expenses of £982,725, including R&D costs of £665,862. The company completed an equity fundraising of £868,698 (net) during H1 2025 and remains debt-free.

Genflow has expanded into ophthalmology and initiated a clinical trial for its GF-1004 therapy in dogs, partnering with Syngene CRO. The company is actively pursuing non-dilutive funding and has received support from the Wallonia Region for GF-1002 development.

Genflow Biosciences PLC (GENFF) reported a significant change in shareholding as Jonathan Mark Swann increased his voting rights in the company. The shareholder's position increased to 8.4% of total voting rights, up from the previous 7.01%, representing 36,588,550 voting rights.

The notification, filed on September 19, 2025, indicates the change occurred through direct acquisition of shares, with no financial instruments or indirect voting rights involved. The transaction was completed in London and reported in accordance with UK regulatory requirements.